Han S H, Kinkhabwala M, Martin P, Holt C, Murray N, Seu P, Rudich S, Hiserodt D, Imagawa D, Busuttil R W
The UCI-UCLA Liver Transplant Program, The University of California, Irvine School of Medicine, USA.
Am J Gastroenterol. 1998 Nov;93(11):2245-7. doi: 10.1111/j.1572-0241.1998.00626.x.
Recurrent hepatitis B infection after orthotopic liver transplantation remains problematic despite prophylaxis with hepatitis B immune globulin (anti-HBs IgG). Recently, famciclovir (an oral nucleoside analog) has been shown to have potent antiviral activity against hepatitis B in vitro as well as in patients with chronic hepatitis B. We present two patients who developed recurrent hepatitis B after orthotopic liver transplantation and were treated with famciclovir, 500 mg t.i.d. Both patients subsequently responded with marked improvement in biochemical liver tests and histology, with subsequent loss of hepatitis B surface antigen. Famciclovir is a useful agent in the treatment of hepatitis B in the liver transplant recipient.
尽管使用乙肝免疫球蛋白（抗-HBs IgG）进行预防，但原位肝移植后乙肝复发仍然是个问题。最近，泛昔洛韦（一种口服核苷类似物）已被证明在体外以及慢性乙肝患者中对乙肝具有强大的抗病毒活性。我们报告了两名原位肝移植后发生乙肝复发并接受泛昔洛韦治疗的患者，剂量为500毫克，每日三次。两名患者随后肝功能生化指标和组织学均有明显改善，随后乙肝表面抗原消失。泛昔洛韦是治疗肝移植受者乙肝的一种有用药物。
